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Available online at www.sciencedirect.comRecent advances in sequencing technologies have revealed
extensive intratumour heterogeneity (ITH) both within individual
tumours and between primary and metastatic tumours for
different cancer types. Such genetic diversity may have clinical
implications for both cancer diagnosis and treatment with
increasing evidence linking ITH and therapeutic resistance.
Nonetheless, whilst limiting the activity of targeted agents,
tumour genetic heterogeneity may provide a new therapeutic
opportunity through generation of neo-antigens that could be
recognised and targeted by the patient’s own immune system
in response to immune-modulatory therapies. Longitudinal
genomic studies assessing tumour clonal architecture and its
correlation with the underlying immune response to cancer in
each particular patient are needed to follow tumour
evolutionary dynamics over time and through therapy, in order
to further understand the mechanisms behind drug resistance
and to inform the development of new combinatorial
therapeutic strategies.
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Introduction
The existence of distinct subpopulations of cancer cells
within a tumour harbouring different behavioural pheno-
types, including tumourigenicity, ability to metastasise
and evolve resistance to treatment, has been recognised
for many years [1]. Recent advances in sequencing tech-
nology have given genetic insight into the extent of
intratumour heterogeneity (ITH) (for review see [2]),
and have contributed to the opinion that ITH is not
simply a tumour characteristic, but through the resolutionwww.sciencedirect.com of distinct subclones, may also have the potential to
forecast risk of tumour progression and therapeutic out-
come. The pattern of genomic instability, and therefore
ITH, in tumours can be generated by different processes
indicative of clinical outcome. Chromosomal instability
(CIN), an initiator of ITH, is associated with poor prog-
nosis in several tumour types [3–5]. Conversely, micro-
satellite instability (MSI), also a driver of ITH, is
associated with good prognosis in colorectal cancers [6].
Therefore, the relationship between ITH and outcome is
likely to be complex and dependent not only on the
mechanisms generating ITH in individual tumours but
also on tumour extrinsic factors such as the potential
indirect impact that different forms of ITH may have
on the host immune response [7].
In this article we review the clinical implications of ITH for
the genetic stratification of tumours, the emerging evi-
dence that suggests the need to investigate the changing
nature of tumour subclonal architecture through therapy
and the potential impact of such diversity on anti-tumour
immunity. We argue that an in-depth understanding of
tumour evolution over time, the mechanisms driving
tumour diversity and its impact on immunity may lead
to the improved management of cancer patients (Figure 1).
Intratumour heterogeneity and clonal
evolution
Phenotypic heterogeneity observed in tumours results
from both genetic and non-genetic causes of heterogen-
eity. Spontaneous tumours are known to arise through
Darwinian-like somatic clonal evolution involving the
acquisition of ‘driver’ events, such as genetic mutations
or copy number variations, believed to affect cancer cell
proliferation or survival, along with ‘passenger’ events,
assumed to be phenotypically silent without a selective
fitness advantage [8]. Non-genetic causes of heterogeneity
include epigenetic changes [9], differentiation hierarchies
as a result of cancer stem cells [10], stochastic biochemical
processes within individual cells and heterogeneous
tumour microenvironments [8]. Processes of genetic diver-
sification promote tumour progression through clonal evol-
ution so that tumours appear to be composed of evolving
cell populations. The linear model of somatic tumour
evolution is that of clonal succession, where a series of
clonal expansions are triggered by the acquisition of driver
events conferring fitness gain, outcompeting and outgrow-
ing other clones [11]. This model implies that tumours are
homogenous for functionally significant mutations, and
whilst some tumours are found to evolve through linearCurrent Opinion in Pharmacology 2013, 13:497–503
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(a) Tumour-intrinsic representation of clonal evolution with eventual outgrowth of resistant subclones due to selection pressures, such as cancer
treatment, and the emergence of new subclones with continued tumour progression. (b) Tumour-extrinsic representation of potential immunological
aspects of clonal evolution. With continued clonal evolution, there is the potential for a broader repertoire of tumour-associated neo-antigens
recognised as non-self leading to increased T cell infiltration with higher T cell receptor binding affinity. As a consequence, the expression of immune
inhibitory receptors, such as PD-1, PDL-1 and CTLA-4, may also be higher. Antibody blockade of such receptors may allow therapeutic intervention
that takes advantage of such neo-antigen heterogeneity within a tumour.steps [12], there is increasing evidence for the existence
of genetically distinct clonal subpopulations with substan-
tial genetic divergence coexisting within different regions
of the same primary tumour, between primary and sec-
ondary tumours, and within metastases [13]. An alterna-
tive model of cancer evolution, distinct from the stepwise
accumulation of somatic genetic alterations, is that of
chromothripsis, in which a cataclysmic one-off genomic
event causes massive DNA alterations acting as a driving
force for cancer development and progression [14].
Evidence for intratumour heterogeneity
Recent advances in massively parallel sequencing tech-
nologies have enabled the analysis of the complexCurrent Opinion in Pharmacology 2013, 13:497–503 clonal architecture of both primary and metastatic
tumours [15]. Patterns of clonal composition indicate
tumour evolutionary paths that underlie tumour pro-
gression. An understanding of such evolutionary
dynamics is essential in deciphering the clonal origins
of metastases and therefore the metastatic process in
general, as well as eliciting the mechanisms underlying
therapeutic resistance. Several studies have demon-
strated genetic diversity within tumours and inferred
tumour progression by comparing the mutations and
clonal composition between primary and metastatic
tumours in different cancer types, including breast,
renal, pancreatic, brain and ovarian (for a review see
[2,16,17]).www.sciencedirect.com
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diagnosis
The validation of predictive biomarkers may be simpler
and less subject to tumour sampling bias when present in
all regions of a tumour and sustained during disease
progression. However, ITH for the expression of genetic
and phenotypic biomarkers has been shown in several
tumour types. In breast cancer, the amplification of HER2
predicts response to trastuzumab but its distribution can
be heterogeneous in primary tumours and associated with
shorter disease-free survival times compared to patients
with homogenous HER2 amplification [18,19]. Yoon et al.
[20] showed that heterogeneous HER2 amplification in
oesophageal adenocarcinoma independently predicted
worse disease-specific survival and overall survival com-
pared to non-heterogeneous HER2 amplified tumours.
Primary and metastatic tumours can evolve indepen-
dently and acquire different phenotypes leading to sig-
nificant genetic divergence, and therefore discordance,
between primary and metastatic tumours in terms of
biomarkers detected in the diagnostic biopsy [21]. In
non-small cell lung cancer (NSCLC), activating
mutations in EGFR predict response to gefitinib, but
discordance for the EGFR mutation has been shown
between primary and metastatic tumours [22,23]. In
primary gastric cancers, heterogeneity of HER2 amplifi-
cation and HER2 protein overexpression has been shown
within the same tumour, and between diagnostic biopsies
and resected tumours [24]. Discordance in HER2 ampli-
fication between primary and metastatic tumours has also
been shown in breast cancer [25,26]. In colorectal cancer,
Vakiani et al. [27] found mutational concordance between
primary and metastatic tumours for KRAS, NRAS, BRAF,
PIK3CA and TP53 genes. However, in patients with a
history of more than one colorectal primary tumour and
interval treatment, there was evidence for discordance in
TP53. These examples demonstrate that relying on a
single tumour biopsy may lead to sampling bias in some
cases and risk missing potentially therapeutically relevant
lesions or contribute to the allocation of a mutation as
actionable without establishing clonal dominance [28].
Furthermore, distinct subclonal populations appear to be
unequally distributed over space and time, indicating that
existing biomarkers are subject to change during disease
progression [29]. This may pose a challenge for thera-
peutic strategies if chosen based on an archival primary
tumour biopsy.
Intratumour heterogeneity and therapeutic
outcome
Most advanced cancers still remain incurable despite
significant progress in the fields of cancer research and
therapy. Response to therapy is generally of limited
duration. This may be due to the inevitable evolution
and proliferation of resistant subclonal populations, which
may exist before the onset of treatment, under thewww.sciencedirect.com selective pressure of therapies [30,31]. In NSCLC,
resistance to the EGFR TKI gefitinib is associated with
the positive selection of cells harbouring the gatekeeper
T790M mutation known to confer insensitivity to gefitinib
[32]. Su et al. [33] demonstrated that in patients with
EGFR mutations treated with EGFR TKIs, the presence
of low frequency subclones harbouring T790M mutations
before the onset of treatment was associated with shorter
progression-free survival, and Turke et al. [34] showed
that the presence of subclones with MET amplification
was associated with EGFR TKI resistance. In colorectal
cancer, wild-type KRAS predicts sensitivity to anti-EGFR
antibody therapies such as panitumumab. Diaz et al.
[31] showed that by monitoring circulating tumour
DNA in patients treated with panitumumab for initially
KRAS wild-type tumours, the emergence of mutations in
KRAS could be detected during the course of therapy
resulting in acquired resistance. They concluded that
subclonal populations harbouring KRAS mutations
existed before commencing treatment, and that under
the selective pressure of anti-EGFR blockade, resistant
subclones rapidly expand and repopulate the tumour. In
chronic myeloid leukaemia and gastrointestinal tumours,
resistance to imatinib due to mutations in the BCR-ABL
fusion protein [35] and KIT [36] respectively, has also
been demonstrated in the context of clonal evolution. It
should be noted that not all cases of therapeutic resistance
are necessarily the result of genetic heterogeneity and
that non-genetic causes, such as stochastic epigenetic
heterogeneity, may also allow the emergence of resistant
clones under selection [37]. These examples demonstrate
that relapsed clones in metastatic tumours can often be
traced back to low frequency subclones before the start of
treatment, hence indicating that the extent of ITH is a
likely important determinant of therapeutic outcome.
In light of increasing evidence in support of ITH and its
role in treatment resistance, there is a need for alternative
therapeutic approaches. Gillies et al. [38] argue that sub-
clonal populations that respond to initial therapy pass
through an evolutionary bottleneck rendering them
highly susceptible to a second therapy [39], and that
drug resistance in this instance, and the choice of this
second therapy, could be anticipated. For example, com-
bined therapy in EGFR mutant NSCLC with an EGFR
TKI and EGFR-specific antibody could prevent resist-
ance associated with the expansion of a subclone harbour-
ing a T790M mutation. Approaches like this would require
the development of biomarkers predicting likely resist-
ance mechanisms in different patients, and such mech-
anisms could be targeted either in combination, or
alternating, with standard treatment regimens [40].
Treatment dosing schedules could be adapted to prolong
the suppression of resistant subpopulations, for example,
drug holidays in androgen-dependent prostate cancer [41]
and melanoma [42]. Other adaptive approaches could
involve combining standard treatment regimens withCurrent Opinion in Pharmacology 2013, 13:497–503
500 Cancerdrugs targeting phenotypes known to contribute to
tumour heterogeneity, such as altered tumour vasculature
and altered glucose metabolism [38].
Intratumour heterogeneity and anti-tumour
immunity
Whilst emerging evidence supports the notion that ITH
limits the efficacy of conventional and targeted thera-
peutics, its overall effect on the immune response to
cancer may still be of potential benefit for the patient
since intratumoural mutational diversity can provide neo-
antigens that may be perceived by the immune system as
non-self, producing unique opportunities for the gener-
ation of anti-tumour immunity. The wealth of data now
being generated through whole genome sequencing of
tumour samples provides further support for this concept.
In silico-based computer algorithms combined with high-
throughput post hoc analyses of data originally generated
by Sjoblom et al. [43] revealed that a significant number of
candidate tumour neo-antigens arise as a consequence of
the multiple gene mutations occurring in breast and
colorectal cancers [44]. Furthermore, previous studies
in colorectal cancers have shown an association between
MSI and good clinical outcomes [6]. MSI is caused by
defects in the DNA mismatch-repair system leading to
progressive accumulation of mutations, in particular
frame-shift mutations that could positively impact immu-
nity. In keeping with this, colorectal tumours with MSI
have distinct pathological features, including increased
tumour-infiltrating lymphocytes, which have also been
associated with better prognosis [45]. One potential
explanation is the greater mutational load in tumours
with MSI in comparison to CIN tumours, which could
result in a higher load of mutated self-peptides or neo-
antigens seen as non-self by the immune system, increas-
ing tumour immunogenicity and promoting enhanced T-
cell activation and tumour infiltration [46]. Based on this,
conventional or targeted agents capable of inducing sub-
stantial tumour cell death might produce an in vivo
‘vaccine’ or priming effect which could be further
enhanced by interference with immune-modulatory path-
ways. Whilst the neo-antigenic repertoire generated by
ITH could be seen as non-self by the immune system, the
type of tumour cell death and inflammatory environment
within the tumour will define their immunogenicity and
the final outcome of the immune response (i.e. tumour
progression versus regression). Importantly, immunity to
tumour-associated antigens can be potentiated given
proper identification and manipulation of immune-regu-
latory checkpoints restricting T cell function [47,48].
This has been recently illustrated by several high profile
clinical trials in which antibody blockade of the immune
inhibitory receptors PD-1, PD-L1 or CTLA-4 produced
significant clinical benefits against a variety of cancers,
including metastatic melanoma [49–52]. In addition to
CTLA-4 and PD-1, a large number of trials are currently
investigating the anti-tumour activity of monoclonalCurrent Opinion in Pharmacology 2013, 13:497–503 antibodies against related inhibitory receptors (Lag-3
and B7-H3), as well as of agonistic antibodies against
immune-stimulatory receptors. In this particular group,
antibodies against different members of the tumour
necrosis receptor (TNFR) family (such as OX40, GITR,
CD40, CD27 and 4-1BB) are under active investigation
either as single agents or in combination with
chemotherapies and targeted-therapies (for a review
see [53]).
Future directions and conclusion
Although ITH may complicate diagnostic and treatment
decisions, it can be clinically useful in predicting clinical
outcome. In Barrett’s oesophagus [54] and breast cancer
[55,56], ITH has been shown to predict invasive pro-
gression. Conversely, extreme CIN, an initiator of ITH,
has been shown to be associated with improved long-term
survival in oestrogen receptor (ER)-negative breast can-
cer [57,58]. Extensive ITH in tumours provides greater
opportunity for adaptive responses to selective pressures
such as hypoxia, chemotherapy and radiotherapy [39]
and therefore, measurements of genetic and phenotypic
heterogeneity may be of significant value in patient risk
stratification [59]. Reliable methods to interrogate
tumours and elicit their underlying clonal architecture
need to be developed in order to test the association
between distinct mechanisms of ITH and clinical out-
come. ITH poses a challenge for effective cancer therapy,
and the resulting heterogeneous expression of biomarkers
may have implications in terms of accurate diagnosis and
treatment outcome [17]. Longitudinal genomic analysis
of tumours at diagnosis, during treatment and at relapse
may inform new approaches and shine a light upon
tumour adaptive mechanisms through therapy. Clinical
trials and biomarker studies should consider such designs
to demonstrate the potential benefit of adaptive therapy
in response to tumour evolution through the disease
course. Obtaining multiple tumour biopsies to study
tumour clonal architecture in such trials may be clinically
challenging but should at least be considered. Potential
non-invasive alternatives to re-biopsy in patients with
multiple or inaccessible metastases may include molecu-
lar imaging and circulating tumour DNA [60].
With the development of improved technologies allowing
the interrogation of ITH, our understanding of tumours
and their evolutionary trajectories may lead to better
design of clinical trials in search of improved therapeutic
interventions to anticipate the emergence of drug resist-
ance mechanisms and generate improved predictive and
prognostic biomarkers [61,62]. Whilst cancer cells cannot
anticipate future evolutionary events or the selective
pressures they may encounter, we should prepare for,
and proactively manage, such changes and use our
acquired knowledge of tumour evolutionary dynamics
to predict and guide treatment strategies in order
to attempt to improve patient outcomes. Underlyingwww.sciencedirect.com
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diversity may in theory result in the generation of neo-
antigens recognised by the immune system as non-self.
The pipeline of new immunotherapeutic drugs offers a
newer and larger window of opportunity through which
tumour sensitivity could be enhanced via the rational
combination of targeted and immune-therapies where
targeted therapies will promote tumour destruction and
neo-antigen exposure (generated through ITH) to the
immune system, whilst manipulation of immune-regulat-
ory pathways will potentially enable a powerful, diverse
and durable response against the tumour.
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